Renal Pelvis and Ureter Carcinoma

Observed

→ investigated in trials for

Gemcitabinesmall molecule

10 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

8 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enfortumab Vedotinadc

7 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Avelumabmonoclonal antibody

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Disitamab Vedotinadc

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Toripalimabmonoclonal antibody

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabozantinibsmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Chemotherapy

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erdafitinibsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Eribulinsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Infigratinibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vinfluninesmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

5-Aminolevulinic Acid

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aldesleukinother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Berzosertibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enzalutamidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinib Hydrochloridesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fluorouracilsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Immunotherapy

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Methotrexatesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mitomycinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pegfilgrastimother

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Rucaparibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sacituzumab Govitecanadc

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tislelizumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tivozanibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tremelimumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vinblastinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Muscle Invasive Renal Pelvis Urothelial Carcinoma

Renal Pelvis and Ureter Carcinoma studied in …STUDIED_INderived10 of 105show all (up to 200)
→ studied in	NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 105 trials mapped (65 active)	—	—	Muscle Invasive Renal Pelvis Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07667335Phase 1/Phase 2 · recruiting Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 105 trials mapped (65 active)	—	—	Renal Pelvis Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04628767Phase 2/Phase 3 · recruiting Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer · condition mapped ONTOLOGY_EXACT · 105 trials mapped (65 active)	—	—	Renal Pelvis and Ureter Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05874921recruiting uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto · condition mapped ALIAS · 105 trials mapped (65 active)	—	—	Renal Pelvis and Ureter Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07498907Phase 3 · recruiting Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma · condition mapped CURATED_BROADER · 105 trials mapped (65 active)	—	—	Renal Pelvis and Ureter Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04963153Phase 1 · active not recruiting Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy · condition mapped CURATED_BROADER · 105 trials mapped (65 active)	—	—	Renal Pelvis Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06948552Phase 2 · recruiting Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA · condition mapped CURATED_BROADER · 105 trials mapped (65 active)	—	—	Renal Pelvis and Ureter Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04940299Phase 2 · active not recruiting Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma · condition mapped CURATED_BROADER · 105 trials mapped (65 active)	—	—	Renal Pelvis Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05494411available Named Patient Program for Mitomycin for Pyelocalyceal Solution · condition mapped ALIAS · 105 trials mapped (65 active)	—	—	Renal Pelvis and Ureter Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 105 trials mapped (65 active)	—	—	Invasive Renal Pelvis Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →

Renal Pelvis and Ureter Carcinoma studied in …STUDIED_INderived10 of 105show all (up to 200)

→ studied in

NCT05987241Phase 2/Phase 3 · recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 105 trials mapped (65 active)

—

Observed

Renal Pelvis Urothelial Carcinoma

→ studied in

NCT07667335Phase 1/Phase 2 · recruiting

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 105 trials mapped (65 active)

—

Observed

Renal Pelvis and Ureter Urothelial Carcinoma

→ studied in

NCT04628767Phase 2/Phase 3 · recruiting

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer · condition mapped ONTOLOGY_EXACT · 105 trials mapped (65 active)

—

Observed

Renal Pelvis and Ureter Urothelial Carcinoma

→ studied in

NCT05874921recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto · condition mapped ALIAS · 105 trials mapped (65 active)

—

Observed

→ studied in

NCT07498907Phase 3 · recruiting

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma · condition mapped CURATED_BROADER · 105 trials mapped (65 active)

—

Observed

Renal Pelvis Urothelial Carcinoma

→ studied in

NCT04963153Phase 1 · active not recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy · condition mapped CURATED_BROADER · 105 trials mapped (65 active)

—

Observed

→ studied in

NCT06948552Phase 2 · recruiting

Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA · condition mapped CURATED_BROADER · 105 trials mapped (65 active)

—

Observed

→ studied in

NCT04940299Phase 2 · active not recruiting

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma · condition mapped CURATED_BROADER · 105 trials mapped (65 active)

—

Renal Pelvis Carcinoma

Observed

Renal Pelvis and Ureter Urothelial Carcinoma

→ studied in

NCT05494411available

Named Patient Program for Mitomycin for Pyelocalyceal Solution · condition mapped ALIAS · 105 trials mapped (65 active)

—

Observed

Invasive Renal Pelvis Sarcomatoid Urothelial Carcinoma

→ studied in

NCT02812420early Phase 1 · active not recruiting

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 105 trials mapped (65 active)

—

Observed